1. Introduction {#s0005}
===============

Major depression is characterized by a persistent low mood or inability to experience usual feelings of pleasure, which is associated with impairments in neurovegetative, psychomotor and cognitive functioning ([@bb0005]; [@bb0405]). Although melancholia has been recognised throughout millennia, current diagnostic criteria are the result of attempts in the past decades to develop reliable, ontological classifications ([@bb0235]). However, the criteria are based only on observable clinical features because no diagnostic pathophysiology has yet been identified. At the present time, major depression is thus a syndrome, which is characterized by a collection of symptoms, rather than a disease with an identifiable pathophysiology.

There is significant heterogeneity in the symptom profiles that can make up a diagnosis, in the clinical outcomes for a given treatment, and in the longitudinal course for individual patients. Addressing heterogeneity is essential, which includes taking into account potential homogeneous factors. Within the heterogeneity in our current classification criteria, we support a core concept of the illness as a primary disorder in mood, in particular a lowering in mood that is embodied in the individual, though we would not expect perfect classification with current diagnostic criteria ([@bb0150]).

We propose that neuroimaging can aid in identifying potential biotypes by quantifying the heterogeneity, as well as homogeneity, that comprise major depression and the biotypes that can predict clinical outcome. We review developments from the initial studies 10 years ago, which had applied machine learning to neuroimaging data to classify major depression and to predict clinical outcome ([@bb0150]; [@bb0155]; [@bb0065]), to replication and progression in international independent datasets ([@bb0125]; [@bb0225]; [@bb0335]), and how heterogeneity is being addressed in recent studies ([@bb0125]; [@bb0090]; [@bb0085]). We review homogeneous mechanisms in psychological and pharmacological therapies, and we discuss the potential to identify biomarkers to predict clinical response. We propose that multitudinous heterogeneous symptom profiles can arise from a limited number of neural patterns as well as how apparently heterogeneous clinical outcomes can include a common baseline predictor of response and common mechanism of treatment.

We conclude with a proposal for the necessary steps and recent developments to identify neuroimaging-based biotypes: 1) harmonization of longitudinal multisite datasets acquired in different scanners and with different image acquisition protocols ([@bb0140]); 2) modelling the pathological process by multiple regularized transformations from the healthy to the patient population to identify the multiple neuroanatomical patterns that characterize disease heterogeneity (CHIMERA) ([@bb0110]); and 3) characterisation of the neuroanatomical heterogeneity through delineation of the multiple hyperplanes within disease populations (HYDRA) ([@bb0375]).

2. Heterogeneity in major depression phenotypes {#s0010}
===============================================

Johannsen ([@bb0220]; reprinted in Johnansen, 2014) introduced the terms: "genotype", which describes the sum of genes in a gamete or zygote; "phenotype", referring what can be readily observed; and "biotype", which represents a given genotype in which biotypes can evolve from each other through small changes in genotype. Our current diagnosis of major depression is a phenotype, and many phenotypic combinations are possible within present diagnostic systems ([@bb0005]; [@bb0405]). In terms of symptoms, there are many potential combinations of clinical profiles, and there is significant clinical comorbidity with anxiety disorders ([@bb0005]; [@bb0405]; [@bb0235]). In terms of the longitudinal course of the illness, it is unknown whether the initial episode will be a single episode, or points to a course of unipolar depression, or is an acute depressive episode of a bipolar disorder (in the present review, 'major depression' refers to 'unipolar depression' in distinction to bipolar disorder). Heterogeneous phenotypes can arise from a common genotype, and seemingly homogeneous phenotypes can arise from different genotypes ([@bb0220]).

Major depression is the leading mental health disorder worldwide, affecting over 350 million people ([@bb0370]). Yet, heritability estimates are around 37% ([@bb0325]), which is relatively low in contrast to bipolar disorder and schizophrenia which have heritability estimates that are consistently up to 90% from twin and molecular genetic studies ([@bb0185]). The heritability of major depression is polygenic, consisting of hundreds of variants and genes, each providing a small component to the genetic contribution, and samples have generally consisted of people of European ancestry ([@bb0205]). Genetic risk variants are not clinically useful at the level of the individual, and how genetic risk progresses into an acute depressive episode is unknown ([@bb0290]).

The genetic and environmental factors that lead to major depression are expressed in subtle and widespread alterations in brain structure and brain function. Magnetic resonance imaging (MRI) has revealed effects in multiple networks, including in frontolimbic circuits and default mode network ([@bb0400]), which are evident in the first episode ([@bb0385]; [@bb0055]) and supported by neuropathological abnormalities ([@bb0040]). Multivariate pattern analysis integrates the subtle and spatially distributed alterations into models, learning to categorise the patterns and then to identify them in new data. Applying machine learning, proof of concept data demonstrated the ability to identify major depression at the level of the individual with high sensitivity and specificity from structural MRI and task-based functional MRI data ([@bb0155]; [@bb0065]; [@bb0280]), and distinct models predicted clinical response at baseline before the start of treatment with measures of confidence of the accuracy of the predictions ([@bb0300]).

Kambeitz et al. ([@bb0225]) meta-analysis of 33 international samples of major depression (*n* = 912) and healthy (*n* = 864) participants demonstrated an overall classification with 77% sensitivity and 78% specificity, based on structural MRI, resting state functional MRI, task-based functional MRI and diffusion tensor imaging. Most studies to date have generated dichotomous classification labels for diagnosis, either major depression or healthy control, primarily due to limited sample sizes of participants with major depression (*n* = 15--57) ([@bb0225]; [@bb0335]). In the largest multisite sample to date, Drysdale et al. ([@bb0125]) were able to identify a number of subtype models based on resting state functional MRI data, which were then validated in independent samples. The models were developed from what would be considered a more treatment-resistant form of depression, that is from participants with major depression (*n* = 220) with active symptoms which had failed to respond to at least two antidepressant treatment trials and while taking medications. The models were then trained in the full sample of depression (*n* = 333) and healthy (*n* = 378) participants and further validated in independent samples of depression (*n* = 125) and healthy (*n* = 352) participants.

A common pattern of altered connectivity was evident, which encompassed the ventromedial prefrontal, orbitofrontal and posterior cingulate cortices, insula, and subcortical regions, and distinct patterns of functional connectivity and clinical symptom profiles were revealed in four subtypes with high sensitivity and specificity (82--92%). Subtype 1 was associated with anxiety, early and middle insomnia, and anergia; subtype 2 was primarily associated with anergia; subtype 3 with anhedonia and psychomotor retardation; and subtype 4 with the highest levels of anxiety, early and middle insomnia, as well as anhedonia. The subtypes were not accounted for by depressive severity only as there were no significant differences in depressive severity scores in subtypes 1, 3 and 4, although there was a modest decrease in subtype 2. Increased thalamic and frontostriatal connectivity associated with anhedonia and psychomotor retardation was most pronounced in subtypes 3 and 4. Reduced fronto-amygdala connectivity associated with anxiety was most severe in subtypes 1 and 4. Reduced connectivity in anterior cingulate and orbitofrontal regions involved in motivation associated with symptoms of anergia and fatigue were most evident in subtypes 1 and 2. By addressing heterogeneity, Drysdale et al. ([@bb0125]) represent an important step in identifying potential biotypes that comprise major depression.

While the highest levels of sensitivity and specificity in classification have been achieved in the treatment-resistant form of depression ([@bb0225]; [@bb0335]), these could be confounded by biological effects of treatment resistance and antidepressant medication on brain structure and function ([@bb0270]; [@bb0145]). From a methodological perspective, Dinga et al. ([@bb0105]) suggest that the clustering algorithm had led to overfitting as their replication analysis could not generate comparable statistically significant subtypes. However, the samples also differed significantly in their clinical characteristics in terms of treatment resistance and depressive state, which are associated with distinct neural correlates ([@bb0270]; [@bb0145]). Drysdale et al. ([@bb0125]) training sample had been based on treatment resistant depression in an acute episode, while Dinga et al. ([@bb0105]) sample (*n* = 178) was comprised of major depression, anxiety disorders, as well as comorbid depression and anxiety disorders, in which about half the sample were in remission or had mild symptoms. The training samples, though larger than the majority of studies to date, could have been sufficiently non-overlapping, were underpowered, and might reflect homogeneity in the neural biotypes of less treatment resistant forms of the illness that are in remission or with few symptoms and which present as heterogeneous clinical phenotypes ([@bb0125]; [@bb0105]).

As a corollary, treatment-resistant depression is currently a clinical diagnosis that refers to a depressive episode that does not improve despite a series of treatments. A predictor model of clinical and sociodemographic data has demonstrated an accuracy of 75% in identifying treatment resistant depression ([@bb0230]). Clinical features in the model though included duration of illness, lifetime duration of hospitalizations and number of depressive episodes, which precludes identification early in the course of the illness. If the treatment resistant biotype is present at the onset of the episode, rather than as a consequence of subsequent treatments, then the biotype might be identifiable early in the illness. Low rates of remission, which is less than one third of treatment trials irrespective of the form of treatment ([@bb0070]; [@bb0180]), indicate that current treatments are insufficient and highlight a subgroup which consistently shows a limited or lack of clinical improvement, suggesting that the pathophysiology of treatment-resistant depression could already be present early in the course of illness.

Common and distinct neural patterns between unipolar major depression and other disorders are another source of heterogeneity. Conjunction analysis of grey matter volumes has observed common reductions in anterior cingulate, dorsomedial and ventromedial prefrontal cortices and insula in unipolar depression and bipolar disorder relative to healthy controls with additional reductions which included right middle frontal and left hippocampus in unipolar depression relative to bipolar disorder ([@bb0400]). Classification results have demonstrated a contribution of reduced grey matter volumes in the anterior cingulate in unipolar depression relative to bipolar disorder ([@bb0315]), although the datasets were based on different samples ([@bb0315]; [@bb0400]).

In addition to the inherent heterogeneity in the disorder, demographic-related factors, such as age, sex and ethnicity, are potential variables which can be controlled for. Most studies have consisted of ethnically homogeneous samples, either predominantly Caucasian or Chinese, raising the issue of whether the models can be generalised to the wider patient population, although we have found proof of principle from a small community sample of African, Asian and Caucasian patients based on structural MRI ([@bb0335]). Furthermore, applying neuroimaging-based biotypes as a model of major depression for genetic studies could improve the specificity of identifying variants for major depression as well as from a greater ethnic diversity, addressing limitations associated with broader definitions of depression and current genetic studies which have most often been assessed in people of European ancestry ([@bb0290]).

Heterogeneity in methodology is a controllable variable. Task-based functional MRI protocols focused on a cognitive task ([@bb0280]) show lower levels of classification accuracy relative to an emotion-based task ([@bb0155]), which is not unexpected in major depression. Overlooking task effects adds variability that is not random, which degrades the quality of the signal and introduces confounds in meta-analyses of classification biomarkers ([@bb0225]; [@bb0260]).

3. Heterogeneity (and homogeneity) in treatment mechanisms {#s0015}
==========================================================

Selective serotonin reuptake inhibitor (SSRI) antidepressants enhance synaptic plasticity, in which the effects on mood might be moderated by environmental stressors ([@bb0195]; [@bb0250]). Pharmacological treatment is associated with increases in regional cerebral volumes, such as in the hippocampus ([@bb0020]). Hippocampal volume is reduced in major depression, which is evident in the first episode ([@bb0055]). SSRI treatment is associated with increased hippocampal volume ([@bb0020]), and an early increase in hippocampal volume following one week of treatment with a serotonin noradrenaline reuptake inhibitor (SNRI) antidepressant was predictive of clinical response ([@bb0170]), which could reflect enhancement in synaptic plasticity and neurogenesis ([@bb0195]; [@bb0250]).

Psychotherapy is an effective treatment for an acute depressive episode, is the preferred form of treatment for many individuals with depression, and demonstrates a sustained benefit in preventing a subsequent depressive relapse ([@bb0200]; [@bb0075]; [@bb0285]). The most common forms of short term psychotherapy are cognitive behavior therapy, behavioral activation, interpersonal therapy, and psychodynamic psychotherapy. Distinct formulations and mechanisms have been proposed, however efficacy has either been comparable or no significant differences have been observed between treatments ([@bb0395]; [@bb0100]; [@bb0095]; [@bb0025]; [@bb0305]). Moreover, our understanding of the neural mechanisms is limited, and there have been remarkably few longitudinal studies of the neural correlates of psychotherapy in depression, about a quarter of the number of pharmacological studies ([@bb0165]; [@bb0340]).

The theoretical formulation of cognitive behavior therapy (CBT) proposes a cognitive triad of biased negative views of onself, one\'s future and experiences in the outside world which leads to characteristic affective and behavioral symptoms ([@bb0030]). CBT attempts to intervene in this cycle by addressing negative cognitions: automatic thoughts (eg. "I\'m a failure") and dysfunctional attitudes (eg. "I should be happy all the time") that in turn reflect schemas and core beliefs which organize new experiences. Cognitive change is a key mechanism in which modifying maladaptive cognitions leads to an improvement in mood ([@bb0030]; [@bb0210]). Behavioral activation therapy focuses on behavioral change to increase engagement in constructive reinforcing activities and to reduce engagement in avoidance and withdrawal behaviours which maintain depression. Behavioral activation refers to the process of changing behaviours in order to engage in positively reinforcing and adaptive activities, which has demonstrated efficacy as a stand-alone component of CBT ([@bb0100]; [@bb0130]).

Interpersonal therapy (IPT) is based on the premise that maladaptive communication processes impact negatively on mood. IPT seeks to address interpersonal difficulties common in depression, focusing on four main themes: bereavement related to the grief and loss of a significant other; role transition due to a life change which affects relationships, such as a new job or loss of functioning; interpersonal disputes in expectations in relationships with significant others; or interpersonal deficits which could be reflected in social isolation or difficulties in maintaining relationships ([@bb0080]). Short term psychodynamic psychotherapy applies support as well as insight to discuss internalized past relationships, intrapersonal patterns and current relationships. Psychodynamic psychotherapy considers how internalized past relationships and unconscious processes could impact on interpersonal relationships and day to day functioning to improve awareness of such processes which in turn aids in the ability to modify responses and behaviours in current behaviours and relationships ([@bb0095]; [@bb0120]).

If a particular process is a mechanism, it is necessary to establish the temporal sequence such it is the specific process which leads to improvements in depressive symptoms ([@bb0245]). As a potential mechanism in CBT, a change in cognition would be expected to precede any improvements in depressive symptoms. In support, early changes in cognition during CBT and "sudden gains" ([@bb0360]; [@bb0365]) as well as therapist adherence to techniques and competence ([@bb0345]) are associated with symptom improvements. However, when changes in mood symptoms were taken into account, early changes in cognitive content no longer predicted subsequent improvements ([@bb0215]). Moreover, improvements in depressive symptoms have also been observed to precede changes in cognitions ([@bb0175]). Component analysis suggests that the effectiveness of CBT can be largely ascribed to behavioral activation ([@bb0210]; [@bb0100]), while acknowledging a predictive component of cognitive change, though assessed as a nominal contribution ([@bb0380]).

Although heterogeneous mechanisms have been proposed, the effects are small. It is well established that common factors contribute to the efficacy of the different forms of psychotherapy. Therapeutic alliance refers to the relationship between the patient and therapist and has consistently demonstrated a mediating effect in clinical outcome to psychotherapy ([@bb0190]), as well as to pharmacological and placebo treatments ([@bb0255]; [@bb0265]). Patient outcome expectations describe the prognostic beliefs about effects of engaging in treatment that could be positive, negative or ambivalent, which show a small association with treatment outcome, which may further be mediated by the therapeutic alliance ([@bb0060]). A common role of the therapist in short term psychotherapy is as an advocate for the patient. The CBT therapist is proposed to represent an active, authoritative advocate for change who supports patients to engage in activities and thoughts, which in turn leads to improvements in depressive symptoms ([@bb0380]). The goal of the IPT therapist is to be the patient\'s ally who reinforces beneficial interpersonal skills and actively reviews adverse outcomes including through role play and rehearsal ([@bb0080]). A range of outcomes has been observed between therapists, in which adherence and competence seem to have a limited effect ([@bb0390]), while therapist adaptiveness and empathy are correlated with clinical outcome ([@bb0135]). How, when and what a therapist responds to in a session reflects their adaptiveness and empathy.

Enhanced synaptic plasticity is a potential common mechanism of antidepressant medication ([@bb0195]; [@bb0250]) and psychotherapy. Synaptic plasticity is a fundamental mechanism in learning and memory ([@bb0355]; [@bb0035]), and learning is an important mechanism in psychotherapy, in which the therapist provides an essential component with whom skills are learned. Moreover, we propose that the patient therapist relationship builds upon inherent models of relationships. Even in the absence of a therapist who is physically present, we would expect that inherent models would have an impact on the perceived relationship, such as in internet-based treatments. We propose that encoding of the relationship is episodic with the repeated sessions of the therapy and that recall of the relationship may be initially explicit.

Furthermore, treatment with CBT ([@bb0160]) as well as treatment with a selective serotonin reuptake inhibitor antidepressant ([@bb9081]; [@bb0015]) has been associated with normalisation of amygdala responses to sad emotional expressions. Encouragement and validation from another person is associated with a reduction in pain ([@bb0050]), in which the emotional-affective dimensions are encoded in the amygdala ([@bb0295]). While support is an inherent component of the patient therapist relationship in both psychological and pharmacological treatments, learning in the context of the patient therapist relationship is potential mechanism, which would have a greater contribution in psychotherapy. Normalisation of amygdala responses could reflect common effects on mood following psychological and pharmacological treatments, in which learning in the context of the patient therapist relationship is a contributing mechanism.

4. Heterogeneity in treatment responsiveness and outcomes {#s0020}
=========================================================

Baseline predictors of clinical outcome reflect factors which indicate the general likelihood of response to a variety of forms of treatments and those which are selective for a particular form of treatment. Irrespective of the mechanism of treatment, the capacity for response will moderate the outcome. If there is an inherent capacity, then there would be general predictor of clinical responsivity to current first line treatments ([@bb0165]; [@bb0180]; [@bb0195]; [@bb0250]). The absence of such marker/s would indicate a reduced likelihood of response.

Short term psychological treatments require the therapist to be an active advocate for the patient ([@bb0030]; [@bb0120]; [@bb0275]; [@bb0010]; [@bb0080]). This could be explicit in the physical presence of the therapist or an inherent implicit presence. Therapeutic alliance is a mediator of treatment outcomes to both pharmacological and psychological treatments ([@bb0190]; [@bb0060]; [@bb0255]; [@bb0265]), but how an individual with depression experiences the interaction with the therapist would be affected in part by their inherent patterns in interactions in close relationships ([@bb0045]; [@bb0320]). Predisposing patterns in interpersonal relationships would moderate treatment outcome as a general predictor of clinical outcome.

If impairments in inherent models of interpersonal relationships moderate clinical outcome to psychological treatments, then factors which impact on their development would contribute to clinical outcome, such as attachment patterns ([@bb0045]; [@bb0320]). Spatial and temporal patterns of interactions between an individual and their attachment figures frame how the individual then perceives and responds in other interpersonal relationships, termed 'internal working models' ([@bb0045]). For example, attachment theory describes how interpersonal relationships evolve from relationships with early caregivers to diverse adult relationships, which are malleable and can continue to develop. It is estimated that 55% of healthy adults have a secure attachment pattern, but it is the insecure attachment profile which predominates in depression and specific subtypes have been associated with poorer clinical outcomes ([@bb0045]; [@bb0320]).

Limited development of inherent models of interpersonal relationships could also be associated with genetic risk load, for example it might be expected that patients with depression with a high genetic risk load for autistic spectrum disorder would prefer an internet based CBT, however, if they have an impaired inherent model of interpersonal relationships, then their ability to interact with and utilise the CBT format would be limited ([@bb0045]), as potentially for any short term therapy which could be transdiagnostic.

Shared features in the forms of therapy include treatment durations, which have mostly been short term in the order of weeks to months, low rates of clinical effectiveness, and the role of the therapist as an active advocate who interacts directly with the patient ([@bb0010]; [@bb0180]; [@bb0350]). However, if the ability of the patient to engage with the therapist depends in part on their inherent models of interpersonal relationships, then impairments in the models would impact on how their relationship develops with the therapist, to which some therapists may be better able to respond and adapt their treatment. This heterogeneity could be evident in part in amygdala responsivity, for example an insecure anxious attachment pattern is associated with increased amygdala response to emotional stimuli ([@bb0310]) and attachment patterns modulate experimentally induced pain ratings in the presence of an observer ([@bb0330]).

5. Addressing heterogeneity {#s0025}
===========================

Being able to identify an acute depressive episode in major depression that is not treatment-resistant, to predict treatment outcome and to predict the course of the illness are key clinical challenges. Model development requires the appropriate data and methodology, which can be summarised, but the quality of the data and methodology are paramount ([@bb0150]; [@bb0090]). In order to reflect clinical practice and to develop models that are not confounded by treatment, the data would be from a community based medication-free population in an acute depressive episode with first episode or recurrent depression that is not treatment-resistant. Well characterized large datasets are required with consideration of ethical and data sharing issues. We would not expect perfect classification with current diagnostic criteria because clinical presentations do not necessarily reflect specific biological measures and do not identify specific pathophysiologies. We would expect an iterative process in which the neuroimaging-based biomarkers are applied to specify potential pathophysiologies ([@bb0150]).

Methods that directly address heterogeneity are essential. Several studies have begun to use high-dimensional clustering methods to dissect imaging heterogeneity in various diseases ([@bb0115]; [@bb0085]; [@bb0240]). While direct clustering of patient data can be informative, it is confounded by variations related to demographics and other factors that are not related to disease pathophysiology. Two semi-supervised learning methods are proposed in an attempt to address this limitation: CHIMERA ([@bb0110]) and HYDRA ([@bb0375]).

CHIMERA is primarily generative, and it assumes that the statistical distribution of imaging features of the (heterogeneous) patient cohort is derived from the statistical distribution of the healthy cohort via a number of transformations that reflect the effects of underlying (heterogeneous) pathophysiologies ([Fig. 1](#f0005){ref-type="fig"}). Covariates are taken into account explicitly. CHIMERA is probabilistic clustering approach that models the pathological process by a combination of multiple regularized transformations from the healthy control population to the patient population. The populations are considered as point distributions which are matched by a variant of the coherent point drift algorithm. For example, a 40 year old woman with depression would have been a 40 year old healthy woman had she been spared the disorder. This is directly modelled in CHIMERA which seeks to identify the multiple imaging patterns that relate to disease effects in order to characterize disease heterogeneity.Fig. 1CHIMERA is a primarily generative method, which assumes that the distribution of measurements from patients (Y, in the figure) is derived from the distribution of controls (X, in the figure), after some (unknown) transformations (T_i) are applied. The latter represent (heterogeneous) disease effects.Fig. 1

HYDRA takes a similar approach, but from the discriminative angle: it uses a number of support vector machine hyperplanes to separate patients from health controls in which each hyperplane reflects one subtype. Covariates are first regressed out of the data. The subtypes are captured by multiple linear hyperplanes which form a convex polytope that separates two populations in which each face of the polytope defines a disease subtype ([Fig. 2](#f0010){ref-type="fig"}). Both methods use cross-validation and split-sample analyses to find the optimal number of subtypes.Fig. 2The HYDRA method is mostly discriminative, in that it attempts to separate patients and controls as well as possible, using multiple hyperplanes, one for each subtype.Fig. 2

The potential of these methods to capture neuroanatomical heterogeneity from MRI has been demonstrated in schizophrenia, mild cognitive impairment and Alzheimer\'s disease ([@bb0115]; [@bb9082]; [@bb0085]; [@bb0240]). Data-driven, inductive modelling strategies model the neuroanatomical patterns that make up major depression as a collection of directions of deviation from normal neuroanatomical patterns. These approaches model the pathological processes associated with depression by a combination of multiple regularized transformations from the healthy control population to the patient population, thereby seeking to identify multiple neuroanatomical patterns that relate to disease effects and to characterize disease heterogeneity. A complementary deductive approach, such as reported clinical symptoms, would apply prior knowledge to identify the linear combinations of neuroanatomical features that correlate with clinical clusters. A synergistic combination could also bring together data-driven inductive and symptom-based deductive approaches such that the clinical measures will be used in CHIMERA and HYDRA to inform the clustering.

Psychological and pharmacological treatments propose distinct heterogeneous mechanisms. Yet, short term psychotherapies advocate an active therapist as a common homogeneous component. If outcomes to short term psychotherapy as well as to antidepressant medication depend in part on inherent models of interpersonal interactions, then this is measurable prior to the initiation of treatment. Measures to date though have been subjective or clinician-rated without a gold standard. Neuroimaging markers offer the potential to characterize the homogeneous as well as heterogeneous mechanisms of clinical effectiveness at the level of the individual with the potential to lead to patient-specific treatments.

In summary, neuroimaging-based biomarkers offer the strongest potential to date to identify the biotypes that comprise our current symptom-based diagnosis of major depression. Increasing sample sizes from multisite collaborations will provide increased power to delineate the neural biotypes that comprise the diagnosis. Among the purported heterogeneous treatment mechanisms, a common factor is the patient clinician relationship. Learning in the context of this relationship is a potential common mechanism which could modulate amygdala responsivity. The inherent model of interpersonal relationships would moderate clinical outcome, which could be associated with genetic risk load and represented by patterns of functional and structural neural correlates. A predictive biomarker would aid in the stratification of the illness, indicating the most appropriate treatment or combination of treatments, which would improve recovery and disability, as well as increase statistical power in treatment studies by reducing heterogeneity in samples. Integrating neuroimaging-based biotypes with genetic studies could aid the specificity in identifying variants. It is essential to directly address heterogeneity in developing biomarkers, in which a synergistic combination could bring together data-driven inductive and symptom-based deductive approaches.
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